Clinical Trial Update: Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a multi-antigen vaccine (MAGE-3/Melan-A/gp100/NA17) with or without rhIL-12 and low-dose IL-2 in metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Interleukin-2 (low-dose IL-2) (interleukin-2)
• MAGE-3/Melan-A/gp100/NA17 vaccine
• rhIL-12 (interleukin-12)

Snippet

Sponsor: University of Chicago | Conditions: Metastatic Melanoma | Phase 2 | Status: COMPLETED